Retrospective analysis of the cell therapy of inhibition of antigen-presentation attenuators combined with adjuvant chemotherapy in the treatment of colon cancer
10.3760/cma.j.issn.1008-6706.2018.24.012
- VernacularTitle:沉默免疫负调控基因技术联合辅助化疗治疗结肠癌的回顾性分析
- Author:
Yonglin ZHU
1
;
Ying HUANG
;
Jinle WANG
;
Bingshou XIE
;
Hongwei DONG
Author Information
1. 温州市人民医院血液科
- Keywords:
Colonic neoplasms;
Gene ttherapy;
Immunity;
Antineoplastic combined chemotherapy protocols;
Adverse drug reaction reporting systems;
Quality of life;
Disease-free survival;
Prognosis
- From:
Chinese Journal of Primary Medicine and Pharmacy
2018;25(24):3175-3179
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect and safety of the cell therapy of inhibition of antigen -presentation attenuators ( iAPA ) combined with adjuvant chemotherapy in the treatment of colon cancer . Methods From February 2014 to October 2015,the clinical data of 40 patients with colon cancer in the People＇s Hospital of Wenzhou were analyzed retrospectively.They were divided into control group and study group by the random digital table,with 20 cases in each group.The control group received mFOLFOX6 chemotherapy(treatment for 6 months),and the study group was treated with iAPA on the basis of the control group (treatment for 6 cycle).The clinical efficacy,levels of immune function indicators ( CD+3,CD+4,CD+8,CD+4/CD+8) before treatment and after treatment,the incidence of toxic and side effects and quality of life (QOL) score of the two groups were recorded.And the survival rates were statistically analyzed.Results The total effective rate of the study group was higher than that of the control group (85.0% vs.55.0%,χ2＝4.286,P＜0.05).After treatment,the serum levels of CD +3,CD+4,CD+8,CD+4/CD+8in the study group were higher than those in the control group,while the serum level of CD +8was lower in the study group than that in the control group,the differences were statistically significant (t＝2.657,3.160,5.700,2.326,all P＜0.05).There were no side effects of the degree of Ⅳin the two groups.The incidence rates of diarrhea(25.0%),vomiting and nausea (20.0%),liver function damage (25.0%) and bone marrow suppression (25.0%) in the study group were lower than those in the control group (χ2＝5.013,5.227,5.013,6.465,all P＜0.05).After treatment,the QOL scores of the two groups were higher than those before treatment (all P＜0.05),and the QOL score of the study group was higher than that of the control group (t＝4.739,P＜0.05).The survival rate of the study group was higher than that of the control group after 24 and 30 months of treatment(χ2＝5.013,4.912,all P＜0.05 ).Conclusion The iAPA combined with adjuvant chemotherapy in the treatment of colon cancer can regulate the immune function of the patients,and improve the treatment effect of the disease.It helps to improve the QOL and prolong the life period of the patients,reduce the incidence of side effects,and it is safe.
